{"denoms":[{"counts":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"121"}],"units":"Participants"}],"groups":[{"description":"Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement ( \\<50 nmol/mmol creatinine).","id":"BG000","title":"Zoledronic Acid Every 12 Weeks"},{"description":"Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement (≥ 50 nmol/mmol creatinine or \\<50 nmol/mmol creatinine, respectively).","id":"BG001","title":"Zoledronic Acid Every 4 Weeks or 12 Weeks"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.91","value":"62.8"},{"groupId":"BG001","spread":"12.66","value":"65.8"},{"groupId":"BG002","spread":"10.99","value":"63.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"57"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"64"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-treat (ITT) analysis set included all participants who were enrolled in this study."}